FIELD: medicine.
SUBSTANCE: application describes a dipeptidyl peptidase IV inhibitor (hereinafter referred to as DPP-IV), which may be a 98.5-100% purity drug contained in a large dose, suitable for direct pressing with special inert fillers into solid dosage forms, such as tablets and capsules, having the necessary hardness, the ability to disintegrate and acceptable dissolution characteristics. By itself, DPP-IV is unsuitable for direct pressing that leads to difficulties in composing compositions. The inert fillers used in the composition improve the flowability and compaction characteristics of the drug and the tableted mixture. Optimal flowability ensures uniform filling of the stamp and mass regulation. The applying binder provides sufficient cohesive ability that makes it possible to compress DPP-IV by direct pressing.
EFFECT: The resulting tablets have an acceptable in vitro dissolution profile.
13 cl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION AND METHOD OF DIRECT COMPRESSING | 2005 |
|
RU2391097C2 |
| SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING COMBINATION OF VILDAGLIPTIN AND GLIQUIDONE | 2014 |
|
RU2585378C1 |
| NOVEL COMPOSITION | 2006 |
|
RU2483716C2 |
| NEW COMPOSITION | 2006 |
|
RU2821230C2 |
| DRY GRANULATION PROCESS FOR PRODUCING TABLET COMPOSITIONS OF METFORMIN AND COMPOSITIONS THEREOF | 2013 |
|
RU2647421C2 |
| DISPERSING TABLETS OF DEFERASIROX | 2005 |
|
RU2396954C2 |
| NEW PHARMACEUTICAL COMPOSITION | 2018 |
|
RU2779429C2 |
| DISPERSED TABLETS DEFERASIROKS | 2003 |
|
RU2338532C2 |
| METHOD OF OBTAINING COMPOSITIONS BY EXTRUSION OF RESISTANT TO PRESSING PHARMACEUTICAL SUBSTANCES | 2006 |
|
RU2405539C2 |
| PHARMACEUTICAL COMPOSITIONS COMPRISING 5,8,14-TRIAZATETRACYCLO[10,3,1,0(2,11),0(4,9)HEXADECA-2( 11),3,5,7,9-PENTAENE | 2002 |
|
RU2272629C2 |
